Clinical trial
Neoadjuvant Combination Immunotherapy for Stage III Melanoma
NCT03842943 is registered in ClinicalTrials.gov with University of Louisville as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Neoadjuvant Combination Immunotherapy for Stage III Melanoma
- Lead sponsor
- University of Louisville
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- July 3, 2019
- Completion date
- June 1, 2028
- Enrollment
- 28 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
cutaneous melanoma